PC
PCVX icon

Pier Capital’s Vaxcyte PCVX Stock Holding History

Pier Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,567
Closed -$5.44M – 141
2024
Q3 		$5.44M Sell
47,567
-67,402
-59% -$6.07M 0.77% 74
2024
Q2 		$8.68M Sell
114,969
-12,415
-10% -$845K 1.29% 23
2024
Q1 		$8.7M Sell
127,384
-74,178
-37% -$5.14M 1.2% 41
2023
Q4 		$12.7M Sell
201,562
-2,166
-1% -$112K 1.81% 3
2023
Q3 		$10.4M Sell
203,728
-2,468
-1% -$122K 1.67% 8
2023
Q2 		$10.3M Buy
206,196
+3,636
+2% +$172K 1.48% 12
2023
Q1 		$7.59M Buy
202,560
+91,355
+82% +$3.88M 1.15% 39
2022
Q4 		$5.33M Buy
+111,205
New +$4.36M 0.87% 57

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pier Capital's PCVX Position: Q4 2024 in Review

Pier Capital sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 47,567 shares — an estimated $5.44M sold.

Pier Capital first reported a position in PCVX in Q4 2022 and held it in 8 quarters. The position peaked at $12.7M in Q4 2023. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Pier Capital reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Pier Capital sold 47,567 Vaxcyte shares in Q4 2024, an estimated $5.44M.
  • Pier Capital first reported a position in Vaxcyte in Q4 2022 and held it in 8 quarters.
  • Pier Capital's Vaxcyte position peaked at $12.7M in Q4 2023.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Pier Capital's 13F filing for Q4 2024, filed 11 Feb 2025.